Consulting Reports

Many of the studies OHE Consulting performs are proprietary and the results are not released publicly. Studies of interest to a wide audience, however, may be made available, in whole or in part, with the client’s permission. They may be published by OHE alone, jointly with the client, or externally in scholarly publications.

The following examples of recent OHE Consulting projects are limited to those with publicly available materials that may be downloaded from this website.

Towse A., Lothgren M., Bruce A, & Steuten L.

Consulting Report
November 2022

An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination or in close sequence (IQVIA, 2019; Bashraheel et al, 2020). Valuing and pricing the components of a combination therapy gives rise to several challenges for companies, payers and HTA bodies particularly when two or more of the products in combination are owned by different companies, each of which seeking a value-based price for their product (Davis, 2014; Greber et al. 2014; Person et al. 2018; Danko et al. 2019).

Firth, I., Hitch, J., Henderson, N. & Cookson, C.

Consulting Report
November 2022

Tackling the climate crisis is an international priority. Healthcare has a high carbon footprint, accounting for 5% of the UK's carbon footprint (Lenzen et al., 2020) and NHS England has estimated that the manufacture, supply, and use of pharmaceuticals account for 25% of the NHS's total carbon footprint (NHS England, 2020).

Besley, S., Henderson, N., Towse, A. & Cole, A. 

Consulting Report
June 2022

Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains, and further benefits for society and health systems. Gene therapy is particularly relevant to rare disease patients, as more than 80 per cent of rare diseases have a known monogenic (single gene) cause. In contrast to traditional small molecule medicines, gene therapies have the potential to correct underlying genetic defects, offering the potential for transformational health gains rather than simply managing symptoms.

Cookson, G. and Hitch, J.

Consulting Report
June 2022

In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth for top-selling medicines. By affecting expected prices and revenues, this type of reform will impact biopharmaceutical companies’ incentives to innovate. However, the magnitudes and timings of impacts on the numbers of new drugs coming to market are unclear.

Mott, D., Schirrmacher, H. & Garau, M. 

Consulting Report
March 2022

Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst this type of measure, which includes commonly used EQ-5D instruments, are useful for enabling comparability between assessments, they might not always capture all the dimensions of QOL that are important to patients.